241 related articles for article (PubMed ID: 34046448)
1. Evaluating Ligand Modifications of the Titanocene and Auranofin Moieties for the Development of More Potent Anticancer Drugs.
Fernandez-Vega L; Ruiz Silva VA; Domínguez-González TM; Claudio-Betancourt S; Toro-Maldonado RE; Capre Maso LC; Ortiz KS; Pérez-Verdejo JA; González JR; Rosado-Fraticelli GT; Meléndez FP; Betancourt Santiago FM; Rivera-Rivera DA; Navarro CM; Bruno Chardón AC; Vera AO; Tinoco AD
Inorganics (Basel); 2020 Feb; 8(2):. PubMed ID: 34046448
[TBL] [Abstract][Full Text] [Related]
2. Bimetallic titanocene-gold phosphane complexes inhibit invasion, metastasis, and angiogenesis-associated signaling molecules in renal cancer.
Elie BT; Fernández-Gallardo J; Curado N; Cornejo MA; Ramos JW; Contel M
Eur J Med Chem; 2019 Jan; 161():310-322. PubMed ID: 30368130
[TBL] [Abstract][Full Text] [Related]
3. New Titanocene (IV) Dicarboxylates with Potential Cytotoxicity: Synthesis, Structure, Stability and Electrochemistry.
Guk DA; Gibadullina KR; Burlutskiy RO; Pavlov KG; Moiseeva AA; Tafeenko VA; Lyssenko KA; Gandalipov ER; Shtil AA; Beloglazkina EK
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834751
[TBL] [Abstract][Full Text] [Related]
4. Next-generation anticancer metallodrugs.
Komeda S; Casini A
Curr Top Med Chem; 2012; 12(3):219-35. PubMed ID: 22236158
[TBL] [Abstract][Full Text] [Related]
5. Auranofin and its analogs as prospective agents for the treatment of colorectal cancer.
Massai L; Cirri D; Marzo T; Messori L
Cancer Drug Resist; 2022; 5(1):1-14. PubMed ID: 35582525
[TBL] [Abstract][Full Text] [Related]
6. Biological Applications of Thiocarbohydrazones and Their Metal Complexes: A Perspective Review.
Bonaccorso C; Marzo T; La Mendola D
Pharmaceuticals (Basel); 2019 Dec; 13(1):. PubMed ID: 31881715
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human topoisomerase I and II and anti-proliferative effects on MCF-7 cells by new titanocene complexes.
Chimento A; Saturnino C; Iacopetta D; Mazzotta R; Caruso A; Plutino MR; Mariconda A; Ramunno A; Sinicropi MS; Pezzi V; Longo P
Bioorg Med Chem; 2015 Nov; 23(22):7302-12. PubMed ID: 26526741
[TBL] [Abstract][Full Text] [Related]
8. Beyond platinums: gold complexes as anticancer agents.
Nardon C; Boscutti G; Fregona D
Anticancer Res; 2014 Jan; 34(1):487-92. PubMed ID: 24403506
[TBL] [Abstract][Full Text] [Related]
9. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
Lazarević T; Rilak A; Bugarčić ŽD
Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
[TBL] [Abstract][Full Text] [Related]
10. The leading established metal-based drugs: a revisitation of their relevant physico-chemical data.
Cirri D; Fabbrini MG; Pratesi A; Ciofi L; Massai L; Marzo T; Messori L
Biometals; 2019 Oct; 32(5):813-817. PubMed ID: 31473877
[TBL] [Abstract][Full Text] [Related]
11. Coordination Complexes of Titanium(IV) for Anticancer Therapy.
Tshuva EY; Miller M
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394027
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative Properties of a Few Auranofin-Related Gold(I) and Silver(I) Complexes in Leukemia Cells and their Interferences with the Ubiquitin Proteasome System.
Cirri D; Schirmeister T; Seo EJ; Efferth T; Massai L; Messori L; Micale N
Molecules; 2020 Sep; 25(19):. PubMed ID: 32998355
[TBL] [Abstract][Full Text] [Related]
13. Anti-proliferative activity and mechanism of action of titanocene dichloride.
Christodoulou CV; Eliopoulos AG; Young LS; Hodgkins L; Ferry DR; Kerr DJ
Br J Cancer; 1998 Jun; 77(12):2088-97. PubMed ID: 9649119
[TBL] [Abstract][Full Text] [Related]
14. Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin.
Cirri D; Fabbrini MG; Massai L; Pillozzi S; Guerri A; Menconi A; Messori L; Marzo T; Pratesi A
Biometals; 2019 Dec; 32(6):939-948. PubMed ID: 31686259
[TBL] [Abstract][Full Text] [Related]
15. Expanding the Therapeutic Potential of the Iron Chelator Deferasirox in the Development of Aqueous Stable Ti(IV) Anticancer Complexes.
Loza-Rosas SA; Vázquez-Salgado AM; Rivero KI; Negrón LJ; Delgado Y; Benjamín-Rivera JA; Vázquez-Maldonado AL; Parks TB; Munet-Colón C; Tinoco AD
Inorg Chem; 2017 Jul; 56(14):7788-7802. PubMed ID: 28644630
[TBL] [Abstract][Full Text] [Related]
16. Titanium(IV) targets phosphoesters on nucleotides: implications for the mechanism of action of the anticancer drug titanocene dichloride.
Guo M; Guo Z; Sadler PJ
J Biol Inorg Chem; 2001 Sep; 6(7):698-707. PubMed ID: 11681703
[TBL] [Abstract][Full Text] [Related]
17. Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?
Kenny RG; Marmion CJ
Chem Rev; 2019 Jan; 119(2):1058-1137. PubMed ID: 30640441
[TBL] [Abstract][Full Text] [Related]
18. Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs.
Michalke B
J Trace Elem Med Biol; 2010 Apr; 24(2):69-77. PubMed ID: 20413063
[TBL] [Abstract][Full Text] [Related]
19. Metal-N-heterocyclic carbene complexes as anti-tumor agents.
Hu C; Li X; Wang W; Zhang R; Deng L
Curr Med Chem; 2014 Apr; 21(10):1220-30. PubMed ID: 24350852
[TBL] [Abstract][Full Text] [Related]
20. Alkaloid-metal based anticancer agents.
Chen ZF; Liu YC; Huang KB; Liang H
Curr Top Med Chem; 2013; 13(17):2104-15. PubMed ID: 23978139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
